IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Jennifer Reed et al.

Confirmation No.: 5470

Application No.: 10/823,253

Group Art Unit: 1644

Filed: April 12, 2004

Examiner: Skelding, Zachary

For: RECOMBINANT IL-9 ANTIBODIES AND

Attorney Docket No.: IL402US

USES THEREOF

DECLARATION UNDER 35 U.S.C. § 132

Mail Stop: AF

COMMISSIONER FOR PATENTS

P.O. BOX 1450

Alexandria, Virginia 22313-1450

Sir:

I, Jennifer Reed, declare:

- 1. I am an inventor of the above-identified application and each of the two provisional patent applications to which it claims priority (provisional application serial number 60/462,259 filed April 11, 2003 and provisional application serial number 60/477,797 filed June 10, 2003).
- 2. I am currently employed as a Senior Scientist in the department of Inflammation and Autoimmunity Research at MedImmune, Inc.
- 3. I have read and understand pages 202 and 203 of provisional application serial number 60/462,259, which describe preparation of IL-9 antibody MAb 2H2.
- 4. IL-9 antibody MAb 2H2 is the same antibody described as 7F3com-2H2 in the instant application.
- 5. Thus, the biological material deposited as ATCC deposit number PTA-5913, described as encoding 7F3com-2H2 in the instant application, is also biological

material encoding IL-9 MAb 2H2, *i.e.*, the antibody described on pages 202 and 203 of application serial number 60/462,259.

- I have reviewed and understand the nucleotide sequence data generated from sequencing the IL-9 antibody encoded in the vector deposited as ATCC deposit number PTA-5913.
- 7. The nucleotide sequence encoding the IL-9 antibody in the vector deposited as ATCC deposit number PTA-5913 indicates that nucleotide position 202 of the variable light chain is a cytosine (as indicated in the amendment to Figure 9B and SEQ ID NO:47 dated May 1, 2006) and not an adenine (as indicated in the originally filed application).

All statements made in this declaration of my own knowledge are true and all statements made in this declaration on information and belief are believed to be true. I understand that willful false statements and the like are punishable by fine or imprisonment, or both (18 U.S.C. § 1001) and may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,

Date January 25, 2007

Jennifer Reed